BING Z CARTER to Dose-Response Relationship, Drug
This is a "connection" page, showing publications BING Z CARTER has written about Dose-Response Relationship, Drug.
Connection Strength
0.036
-
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673.
Score: 0.024
-
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6.
Score: 0.012